3 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Resection: new trials by email Literature Review of Resection trials Research Report on Resection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment Durvalumab, Tremelimumab, Pemetrexed - Stage III NSCLC | Phase 1 | Terminated | The Netherlands Cancer Institute | 18 | 2018-12-28 | 2024-11-06 |
| Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer CRLX101, Capecitabine, Radiotherapy - Rectal Cancer | Phase 1 / Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 32 | 2013-12-01 | 2020-11-03 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neuroblastoma (1) · Osteosarcoma (1) · Rectal Neoplasms (1)
National Cancer Institute (NCI) (1) · The Netherlands Cancer Institute (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (2) · Canada (1) · Netherlands (1)
Andrew Wang, MD (1) · Robbie G Majzner (1) · W Theelen, MD (1)
P30CA015704 (1), U01CA154967 (1), UM1CA228823 (1)